<DOC>
	<DOCNO>NCT02082665</DOCNO>
	<brief_summary>This open-label , multi-center , fix sequence study subject BRAF V600 mutation positive tumor . Subjects receive single oral dos 10 milligram ( mg ) rosuvastatin 3 mg midazolam morning Day 1 ( alone ) , Day 8 ( first dose dabrafenib 150 mg ) , Day 22 ( repeat dose dabrafenib 150 mg twice daily [ BID ] ) . Dabrafenib 150 mg BID administer Day 8 Day 23 . Blood sample PK analysis obtain 32 hour post-dose Day 1 , Day 8 , Day 22 . The last dose dabrafenib take morning Day 23 last blood sample even Day 23 . Subjects consider complete study 32 hour PK sample collect Day 23 . Once complete study , eligible subject may option enter study BRF114144 , open-label roll-over study dabrafenib ( follow-up visit require ) continue receive dabrafenib .</brief_summary>
	<brief_title>Effects Dabrafenib Single Dose Pharmacokinetics ( PK ) Rosuvastatin Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Signed , write informed consent . BRAF V600 mutationpositive tumor : confirmed Clinical Laboratory Improvement Amendments ( CLIA ) approve local laboratory equivalent . Male female 18 65 year age , inclusive , time signing informed consent form ; Capable compliance requirement restriction list consent form ; Body weight &gt; = 45 kilogram ( kg ) body mass index &gt; = 19 kilogram per squaremeter ( kg/m^2 ) &lt; 40 kg/m^2 ( inclusive ) ; Able swallow retain orally administer medication Eastern Cooperative Oncology Group ( ECOG ) performance status : 0 1 . NOTE : Subjects performance status 2 enrol subject 's confinement bed inability carry work activity due solely cancerrelated pain , assess Investigator . Adequate baseline organ function define : absolute neutrophil count &gt; = 1.2 x 10^9/Liter ( L ) ; hemoglobin &gt; =9 gram per deciliter ( g/dL ) ; platelet &gt; = 75 x 10^9/L ; prothrombin time /international normalize ratio partial thromboplastin time = &lt; 1.3 x ULN ; serum bilirubin= &lt; 1.5 time upper limit normal ( ULN ) ; aspartate aminotransferase alanine aminotransferase = &lt; 2.5 time ULN ; serum creatinine= &lt; 1.5 mg/dL calculate creatinine clearance &gt; = 50 milliliter per minute ; Left ventricular ejection fraction &gt; = low limit normal echocardiography . Women childbearing potential must willing practice acceptable method birth control . Additionally , woman childbearing potential must negative serum pregnancy test within 14 day prior first dose study medication . History another malignancy exception , malignancy confirm activate RAS mutation . Exception : ( ) Subjects successfully treat diseasefree 5 year , ( b ) history completely resect nonmelanoma skin cancer , ( c ) successfully treat situ carcinoma , ( ) chronic lymphocytic leukemia stable remission , ( e ) indolent prostate cancer ( definition : clinical stage T1 T2a , Gleason score &lt; =6 , prostatespecific antigen &lt; 10 nanogram per milliliter ) require antihormonal therapy , eligible . Note : Prospective RAS testing require . However , result previous RAS test know , must use assess eligibility . Cancer therapy ( chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) investigational anticancer drug within last 3 week , chemotherapy without delayed toxicity within last 2 week , precede first dose study medication . Unresolved clinically significant toxicity great Grade 2 previous anticancer therapy Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure . Current use therapeutic warfarin . NOTE : Low molecular weight heparin prophylactic lowdose warfarin permit Any prohibited medication ( ) herbal preparation describe protocol require medication study . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate dabrafenib , rosuvastatin , midazolam , excipients contraindicate participation ; allergy cherry . Pregnant nursing female . A history evidence cardiovascular risk include follow : A QT interval correct heart rate use Bazett 's formula ( QTcB ) &gt; =480 millisecond ( msec ) ; A history evidence current clinically significant uncontrolled arrhythmia ; A history acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization A history evidence current &gt; =Class II congestive heart failure define New York Heart Association ( NYHA ) guideline Abnormal cardiac valve morphology ( &gt; =grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study . Patients intracardiac defibrillator Presence active GI disease condition ( e.g. , small bowel large bowel resection ) interfere significantly absorption drug . If clarification need whether condition significantly affect absorption drug , contact GSK Medical Monitor . Subjects COPD subject increase risk respiratory depression Subjects narrow angle glaucoma A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus , Hepatitis C Virus infection . Subjects brain metastasis exclude brain metastasis : Symptomatic ; Treated ( surgery , radiation therapy ) clinically radiographically stable one month local therapy , OR ; Asymptomatic untreated &gt; 1 cm long dimension . Subjects small ( &lt; = 1 cm long dimension ) , asymptomatic brain metastasis need immediate local therapy enrol . Subjects stable dose corticosteroid one month , corticosteroid least 2 week enrol . Subjects must also enzymeinducing anticonvulsant 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rosuvastatin</keyword>
	<keyword>BRAF V600</keyword>
	<keyword>Melanoma</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>midazolam</keyword>
</DOC>